AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NovoCure Ltd Director's Dealing 2022

Aug 3, 2022

31949_dirs_2022-08-03_aa1e8b70-5901-4ed5-8abd-8f530c339f39.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-08-02

Reporting Person: Cordova Ashley (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-02	Ordinary Shares	A	7122	$70.20	Acquired	73261	Direct

Footnotes

F1: Represents restricted share units that are scheduled to vest in equal installments on each of August 2, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.